Company profile
UK company 10803595, incorporated on 5 June 2017.
Atelerix - A ground-breaking solution for cell preservation.
The Atelerix technology provides an innovative solution for storing and transporting cells and tissues at room temperature.
Company number 10803595
Financial period: 1 Jul 2023 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
AA | Transaction MzU0ODQ4MzkwN2FkaXF6a2N4
Published 30 Sep 2026 10:26
CS01 | Transaction MzUzNzUxOTI3NmFkaXF6a2N4
Published 09 Aug 2026 07:46
Company registered at Companies House
Atelerix develops technology designed to improve the storage and transport of human cells.
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: - Predictability and reliability in drug discovery models and for cells used as therapies - Customers can use cells and assays immediately on arrival - No need for cryopreservation, nor need for cytotoxic or animal-derived supplements - Cells retain their natural state and are not damaged nor altered
2022 Clinical trial using alginate to store and then clinically use stem cells completed
Currently employing 3 x FTE, two of these are full time scientific posts. Market valuation in excess of 1 million pounds based upon investment raised within first 6 months of operation. MoU agreed between Atelerix and LV Prasad Eye Institute, India for the joint development of simple stem cell therapy.
1 May 2024 to 30 Apr 2025
Current delivery of cells for drug discovery has severe drawbacks that prevent efficiency and market availability. Typically, cells are shipped cryopreserved within the UK and internationally. Maintaining the cells in a frozen state is one of the biggest challenges in cell transportation and requires the use of heavy, non-environmentally friendly dry ice ...
1 Jan 2022 to 31 Mar 2023
As the UK shifts towards an ageing population the rates of disease associated with ageing, including cancers, will rise and the UK healthcare system will be placed under additional stress. To improve disease diagnostics and treatment, the healthcare sector is moving towards a more personalised, individually focussed approach. However, research and develop...
1 Mar 2021 to 31 Jul 2023
Good fertility performance is the cornerstone of a profitable and sustainable livestock enterprise. In the international dairy and beef herd, optimum performance is achieved by maintaining a calving interval (CI) of 365 days. Every day CI increases \>365 days is estimated to directly cost the farmer ~GBP2.07/CAN$3.54/cow, or more for high yielding dairy c...
1 Nov 2020 to 31 Dec 2021
1 Jun 2020 to 28 Feb 2021
More than 380,000 people have been tested for COVID-19 in the UK, with less than 20,000 samples being collected daily. The government plans to escalate testing more than five-fold to 100,000 daily samples. However, a severe limitation of swab samples which collect infected cells from the upper respiratory tract is their short shelf-life of only 48-72 hour...
1 Sep 2019 to 31 May 2021
"Therapies using live cells offer the possibility of treatments for diseases and conditions that cannot be approached by conventional drugs. Cells are being investigated for their abilities to reverse blindness, re-grow bone and nerves, restore the immune system and treat cancers for which there are no effective drugs. Living cells, however, are fragile a...
